Skip to content
PepIndex

Research

What the evidence actually shows

Start with the explainers — the category-level questions worth answering before you read anything else. Below them, a dated regulatory feed tracks approvals, warning letters and shortage movements; a structured study index gives every study a permalink; and an evidence digest for every compound waits at the bottom, one search away, stating what the literature supports and — as a required section — what it does not.

2 explainers · 11 regulatory entries · 102 studies indexed, 97 human · 28 compound digests

Start here

Plain-English explainers
  1. 1Origin LabsILS Laboratories · 25 certificates96.9of 100Extensively documentedVisit Origin Labs
  2. 2Next Gen PeptidesILS Laboratories · 114 certificates93.6of 100Extensively documentedVisit Next Gen Peptides
  3. 3Amino ClubILS Laboratories · 23 certificates90.5of 100Extensively documentedVisit Amino Club

What any vial contains is answered by that vendor's certificate records, not by the studies on these pages. Some outbound links are partner links; partner status cannot reach the scoring code.

Reports and guides

Long-form, newest first

Regulatory feed

Dated entries tracking approvals, compounding-list movements, warning letters, shortage status and prohibited-list revisions — including recent FDA action against vendors selling GLP-1 and research peptides direct to the public.

EMAApproval

EMA medicine approvals — GLP-1 and dual-agonist products

The European Medicines Agency publishes decisions on marketing authorisation. Approval status matters to this index because it determines whether the substance in a research-grade vial has an approved counterpart at all — and therefore whether a published trial literature exists for a product that is not the one being sold.

SemaglutideTirzepatide

FDACompounding list

FDA bulk drug substances nominated for compounding — 503A and 503B lists

The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.

SemaglutideBPC-157IpamorelinCJC-1295

FDAShortage list

FDA drug shortage database — GLP-1 receptor agonist products

Shortage status for approved GLP-1 products materially affects this market: when an approved product is listed as in shortage, compounding of that substance becomes permissible under conditions, and demand shifts toward alternative supply. Resolution of a shortage reverses that. PepIndex records status changes here because they move the whole category.

SemaglutideTirzepatide

FDAWarning letter

FDA warning letter database — research chemical and peptide sellers

The FDA publishes warning letters issued to firms, including sellers marketing unapproved products or making disease claims. Where a letter names a vendor tracked in this index, PepIndex records it here and links it from that vendor's profile. No vendor currently in the index has such a letter recorded against it.

MHRAGuidance

MHRA position on unlicensed medicines sold direct to the public

The UK regulator has published guidance and enforcement positions on the supply of unlicensed medicines to the public, including substances marketed as research chemicals. Several compounds tracked here have been the subject of public statements. PepIndex records those affecting indexed compounds.

Melanotan II

WADAProhibited list

WADA Prohibited List — growth factors and peptide hormones (class S2)

The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.

IpamorelinCJC-1295TB-500

Every study is stored once and referenced wherever it is relevant. Each has a permalink, an evidence type, the model it used and what it reported.

Per-compound research digests

Evergreen · one per compound
Studies indexed
102
Human evidence
97
Preclinical only
5

Across every compound tracked, most of the indexed literature is preclinical — the single most useful thing to know before reading any digest below.

Pick a compound above to read what the published literature does — and, just as importantly, does not — establish for it.